PHASE II TRIAL OF EMD 121974 FOR RECURRENT GLIOBLASTOMA: A CLINICAL TRIAL WIT

EMD 121974 治疗复发性胶质母细胞瘤的 II 期试验：临床试验智慧

• 批准号: 7606797
• 负责人: TIMOTHY CLOUGHESY
• 金额: $ 6.63万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-21 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606797
• 关键词: Adverse effects; Brain Neoplasms; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; EMD 121974 (Cilengitide); Funding; Glioblastoma; Grant; Institution; Patients; Phase II Clinical Trials; Recurrence; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Wit; prevent; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: ¿ Evaluate how effective EMD 121974 is in treating brain tumors. In this phase II study, we will determine whether EMD 121974 has any activity in preventing the regrowth of the brain tumor. ¿ We will also determine the effect of EMD 121974 by surgically removing tumor after 3 treatments with EMD121974. ¿ Determine the safety and side effects of EMD 121974 when given to patients with brain tumors.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： ¿ 评价EMD 121974治疗脑肿瘤的有效性。 在这项II期研究中，我们将确定EMD 121974是否具有预防脑肿瘤再生长的活性。 ¿ 我们还将通过在3次EMD 121974治疗后手术切除肿瘤来确定EMD 121974的作用。 ¿ 确定脑肿瘤患者服用EMD 121974的安全性和副作用。